One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...